Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 8, 2013, Pages 1446-1450

  Niccolai, Linda M ^a   Julian, Pamela J ^a   Meek, James I ^a   McBride, Vanessa ^a   Hadler, James L ^a   Sosa, Lynn E ^b  

^a YALE UNIVERSITY   (United States)

^b CDC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER REGISTRY; ETHNICITY; FEMALE; HEALTH DISPARITY; HUMAN; MAJOR CLINICAL STUDY; POVERTY; PRIORITY JOURNAL; URBAN AREA; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONNECTICUT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NEOPLASM GRADING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84882243131     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0272     Document Type: Article

References (29)

1. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007;121:621-32.
2. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
3. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
4. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind randomized trial in young women. Lancet 2009;374:301-14.
5. Centers for Disease Control and Prevention. National, state and local area vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep 2009;58: 997-1001.
6. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:671-7.
7. Centers for Disease Control and Prevention. Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61: 66-72.
8. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: An analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012;102:833-5.
9. Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012;130:e249-56.
10. Read TRH, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87:544-7.
11. Brotherton JML, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological analysis. Lancet 2011;377:2085-92.
12. Leval A, Herweijer E, Arnheim-Dahlstrom L, Frans E, Sparen P, Simard JF. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012;206: 860-6.
13. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS. Evaluating the impact of human papillomaviruses. Vaccine 2009;27:4355-62.
14. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
15. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008;35:519-36.
16. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management ofwomen with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-5.
17. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20.
18. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG 2002;109:364-8.
19. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, et al. The HPV vaccine impact monitoring project (HPV-IMPACT): Assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 2012;23:281-8.
20. Niccolai LM, Julian PJ, Bilinski A, Mehta NR, Meek JI, Zelterman D, et al. Area-based poverty, racial, and ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. Am J Public Health 2013;103:156-63.
21. Federal Financial Institutions Examination Council. [Accessed March 26, 2012]. Available from: Http://www.ffiec.gov/geocode.
22. Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV. Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: The Public Health Disparities Geocoding Project. Am J Public Health 2005;95:312-23.
23. Krieger N, Chen JT, Waterman PD, Soobader M-J, Subramanian SV, Carson R. Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: Does the choice of area-based measure and geographic level matter?: The Public Health Disparities Geocoding Project. Am J Epidemiol 2002;156:471-82.
24. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009; 114:40-420.
25. Moyer VA,U.S Preventive Services Task Force. Screening for cervical cancer: US preventive services task force recommendation statement. Ann Internal Med 2012;156:880-91.
26. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-42.
27. Hariri S, Unger ER, Powell SE, Bauer HM, Bennett NM, Bloch KC, et al. Human papillomavirus genotypes in high grade cervical lesions in the United States. J Infect Dis 2012;206:1878-86.
28. Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, et al. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty. Cancer 2013 May 9. [Epub ahead of print].
29. Apgar BS, Kittendorf AL, Bettcher CM,WongJ, Kaufman AJ. Update of ASCCP consensus guidelines for abnormal cervical screening tests and cervical history. Amer Fam Phys 2009;80:147-55.